Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

Academic Article


  • We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of ≥1.6 log 10 copies/ml at all twice daily doses ≥100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach. © 2005 Nature Publishing Group.
  • Digital Object Identifier (doi)

    Pubmed Id

  • 18545114
  • Author List

  • Fätkenheuer G; Pozniak AL; Johnson MA; Plettenberg A; Staszewski S; Hoepelman AIM; Saag MS; Goebel FD; Rockstroh JK; Dezube BJ
  • Start Page

  • 1170
  • End Page

  • 1172
  • Volume

  • 11
  • Issue

  • 11